Sonntag, 20. Juni 2021
Navigation öffnen
Anzeige:
Canakinumab
Canakinumab
 
JOURNAL ONKOLOGIE – STUDIE

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Rekrutierend

NCT-Nummer:
NCT03275402

Studienbeginn:
Dezember 2018

Letztes Update:
27.04.2021

Wirkstoff:
131I-omburtamab

Indikation (Clinical Trials):
Neoplasm Metastasis, Neoplasms, Second Primary, Neuroblastoma, Meningeal Carcinomatosis

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
Y-mAbs Therapeutics

Collaborator:
-

Studienleiter

Agon Hyseni, MD
Study Director
Y-mAbs Therapeutics

Kontakt

Studienlocations
(3 von 12)

University of Florida
32611 Gainesville
United StatesAbgeschlossen» Google-Maps
Riley Hospital for Children
46202 Indianapolis
United StatesRekrutierend» Google-Maps
Memorial Sloan Kettering Cancer Center
10065 New York
United StatesRekrutierend» Google-Maps
Nationwide Children's Hospital
43205 Columbus
United StatesAktiv, nicht rekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Detailed Description:

One 131I-omburtamab treatment cycle takes 4 weeks and includes a treatment dose, and an

observation period and post-treatment evaluations.

One 131I-omburtamab treatment cycle for Japan only takes 5 weeks and includes a dosimetry

dose (2mCi) of 131I-omburtamab is administered during week 1 followed by blood/cerebral

spinal fluid (CSF) samples and whole-body scintigraphy at predefined intervals during the

following 48 hours after treatment.

- A therapeutic dose (50mCi) of 131I-omburtamab is administered during week 1 (week 2 for

Japan) followed by a 3-week observation period that includes a repeated MRI, CSF

cytology, and safety monitoring.

- A second treatment cycle of 131I-omburtamab is administered during week 5 (week 6 for

Japan) if there is no objective disease progression week 5 after the first injection,

and the participant is presenting without unexpected and clinical significant Grade 4

toxicity. For participants with ongoing Grade 3 toxicity a second doing cycle will take

place according to the discretion of the investigator.

Participants can be treated in an outpatient setting or may be admitted as inpatients for

both the dosimetry and the therapeutic injections.

Participants completing at least one treatment period will first enter a follow-up period

through week 26 and thereafter the long-term follow-up where patients will be evaluated for

up to 3 years post-131I-omburtamab treatment where after the trial is ended

Participants will be monitored for adverse events during and after 131I-omburtamab injection

and will have pre- and post-treatment clinical assessments including neurologic examination,

hematology and serum chemistry, blood and CSF cultures, endocrinology assessments, CSF

analysis, and, pre- and post 131I-omburtamab performance testing. Performance testing will be

performed at trial baseline, at week 26 and every 6 months during trial period.

In case the patient has a subsequent relapse in the CNS/LM after 131I-omburtamab therapy

during the follow-up period, re-treatment to target minimal residual disease can be

considered and allowed.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Patients must have a histologically confirmed diagnosis of neuroblastoma with relapse

in the central nervous system or in the meninges (leptomeningeal).

- Patients must be between the ages of birth and 18 years at the time of screening.

- Patients must have a life expectancy of at least 3 months.

Exclusion Criteria:

- Patients with primary neuroblastoma in central nervous system.

- Patients must not have an uncontrolled life-threatening infection.

- Patients must not have received cranial or spinal irradiation less than 3 weeks prior

to first dose of 131I-omburtamab in this trial.

- Patients must not have received systemic chemotherapy (corticosteroids not included)

less than 3 weeks prior to enrollment in this trial.

- Patients must not have severe major non-hematologic organ toxicity; specifically, any

renal, cardiac, hepatic, pulmonary, and gastrointestinal system toxicity must fall

below Grade 3 prior to enrollment in this trial. Patients with stable neurological

deficits (due to brain tumor) are not excluded. Patients with Grade 3 or lower hearing

loss are not excluded.

Studien-Rationale

Primary outcome:

1. Overall survival rate (Time Frame - 3 years):
Overall survival rate at 3 years after the first treatment dose of 131I-omburtamab.



Secondary outcome:

1. Overall survival (Time Frame - 3 years):
Overall survival at 3 years after the first treatment dose of 131I-omburtamab.

2. Objective response rate (ORR) (Time Frame - 3 years):
ORR is defined and assessed as a combination of partial response and complete response as defined by the RANO criteria and CSF cytology.

3. Objective response rate (ORR) (Time Frame - 3 years):
ORR according to CSF cytology. ORR is defined and assessed as a combination of partial response and complete response.

4. CNS progression free survival (PFS) (Time Frame - 6 month):
CNS PFS will be assessed at 6 months after the first treatment dose of 131I-omburtamab by comparing baseline radiological scans by MRI to radiological scans conducted 26 weeks after 131I-omburtamab treatment.

5. Dosimetry of 131I-omburtamab (Time Frame - 2 weeks):
Whole-body, organ, blood, and CSF radiation dosimetry.

6. Assessment of peak plasma concentration (Cmax) of 131I-omburtamab (Time Frame - Baseline, 30 minutes, 1 hour, 4 hour, 1, 2, 3 and 7 days):
Cmax will be calculated and summarized with descriptive statistics.

7. Assessment of residence time of 131I-omburtamab (Time Frame - Baseline, 30 minutes, 1 hour, 4 hour, 1, 2, 3 and 7 days.):
Residence time will be calculated and summarized with descriptive statistics.

8. Assessment of elimination half-life of 131I-omburtamab (Time Frame - Baseline, 30 minutes, 1 hour, 4 hour, 1, 2, 3 and 7 days.):
Elimination half-life will be calculated and summarized with descriptive statistics.

9. Safety of 131I-omburtamab (Time Frame - 3 years):
The frequency, type, and duration of treatment-emergent severe adverse events and serious adverse events, including clinically significant laboratory abnormalities. All adverse events will be graded according to CTCAE, version 4.0.

10. Performance assessment (Time Frame - 3 years):
Performance assessment to monitor gross changes in neurological function is performed at week 26 and subsequently every 6 months during trial period using Lansky (< 16 years) and Karnofsky (≥ 16 years).

Geprüfte Regime

  • 131I-omburtamab (131I-8H9):
    Murine IgG1 monoclonal antibody radiolabeled with iodine-131

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Gesundheitsversorgung auf dem Land – weite Wege, lange Wartezeiten
Gesundheitsversorgung+auf+dem+Land+%E2%80%93+weite+Wege%2C+lange+Wartezeiten
Krebsinformationsdienst, DKFZ

Eine repräsentative Umfrage* vom Dezember 2017 hat gezeigt: Die medizinische Versorgung in ländlichen Regionen weist aus Sicht vieler Befragter Defizite auf. Bemängelt wurden lange Wartezeiten auf Arzttermine, weite Wege und weniger Informationsmöglichkeiten. Auch für Krebspatienten und ihre Angehörigen kann diese Situation belastend sein. Der Krebsinformationsdienst des Deutschen Krebsforschungszentrums ersetzt...

Biopharmazeutika sind den meisten Deutschen unbekannt
Biopharmazeutika+sind+den+meisten+Deutschen+unbekannt
© Darren Baker / Fotolia.com

Naturheilmittel oder neuer Trend der Bio-Welle? 94 Prozent der Deutschen können mit dem Begriff Biopharmazeutika nichts anfangen (1). Oftmals werden hinter dem Begriff Naturheilmittel vermutet. Dabei handelt es sich um Arzneimittel, die biotechnisch hergestellt oder aus gentechnisch veränderten Organismen gewonnen werden und mit dem Ziel der Bekämpfung einer Krankheit in die Vorgänge des Körpers eingreifen. Insulin...

EHA 2021
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose
  • Hochrisiko-MDS und AML: Sabatolimab + Decitabin/Azacitidin zeigt in Phase-I-Studie anhaltende Remissionen bei guter Verträglichkeit
  • PNH: Neuer oraler Faktor-B-Inhibitor Iptacopan zeigt in Phase-II-Studie Wirksamkeit in der Erstlinie